Dermatology Daily Report: 01/26/2024

A randomized, placebo- and active-controlled, double-blind phase 3 clinical trial (COMFORT-1) investigated the effect of piclidenoson in 529 patients with moderate-to-severe plaque psoriasis and found the primary end point was met with the 3 mg BID dose, showing a PASI 75 rate of 9.7% versus 2.6% for piclidenoson versus placebo, p = 0.037 (1). At week 32, a greater proportion of patients in the piclidenoson 3 mg BID arm achieved improvement from baseline in Psoriasis Disability Index (PDI) compared to apremilast, with a favourable safety profile. The study (ClinicalTrials.gov identifier: NCT03168256) supports the continued clinical development of piclidenoson as a psoriasis treatment.

Reference

Papp KA, Beyska-Rizova S, Gantcheva ML, Slavcheva Simeonova E, Brezoev P, Celic M, Groppa L, Blicharski T, Selmanagic A, Kalicka-Dudzik M, Calin CA, Trailovic N, Ramon M, Bareket-Samish A, Harpaz Z, Farbstein M, Silverman MH, Fishman P; COMFORT-1 Study Investigators. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1). J Eur Acad Dermatol Venereol. 2024 Jan 26. doi: 10.1111/jdv.19811. Epub ahead of print. PMID: 38279575.